{"effect":{"id":"constipation","name":"Constipation","severity":"mild","description":"Difficulty passing stools or less frequent bowel movements. The FDA Wegovy prescribing information (revised 06/2026) lists it among the most common adverse reactions — 24% on semaglutide 2.4 mg (N=2,116) versus 11% on placebo (N=1,261), Table 3 — and separately states that semaglutide delays gastric emptying (section 12.2). It attributes constipation to no mechanism, and neither do we.","clinicalRates":{"low":0.05,"medium":0.12,"high":0.18},"clinicalRatesNote":"A fixed reference table dated 2026-04-12, not derived from this corpus and carrying no per-effect citation of its own — see `sources` on ?q=effect&id=<id> for what was recorded behind each effect. It reaches published numbers two ways. (1) As the sole clinical base for an effect with no eligible corpus rate point — exactly the effects whose pooled corpus estimate is null (corpusClinical here, rateBase.clinical.pooledEstimate on the per-effect endpoint); the predictor marks these isFallback: true. (2) Since 2026-08-28, as a dose-tier rescale ratio applied to the corpus's OWN pooled rate wherever that tier's pooled clinical records are mostly dose-untagged; isFallback stays false in that case, and the predictor's clinical.basis states both endpoints and the dose-tag denominator while clinical.pooledPercentage carries the corpus rate before any adjustment. Full per-source detail: rateBase.clinical via ?q=effect&id=<id>. WITHDRAWN 2026-09-03 (decision literature-fallback-clinical-rate-2026-08-28, option c) for emotional_blunting only: this table had no rate-stating source at all for it, so its clinicalRate fields are null here and its predictor track carries `available: false` with no percentage — see clinicalRatesWithdrawn on ?q=effect&id=emotional_blunting. RE-SOURCED 2026-09-03 (same decision, option b) for fatigue only: its three tier values are one figure, 0.11, from the FDA Wegovy prescribing information revised 06/2026 (Table 3: fatigue incl. asthenia 11% on 2.4 mg, N=2,116, vs 5% placebo, N=1,261; URL in its sources) — the label reports no per-dose-tier rate, so no gradient is published for it, and it is a semaglutide figure applied at every dose tier regardless of molecule, as this whole table is. RE-SOURCED 2026-09-04 (decision pancreatitis-hairloss-dizziness-triple-derivation-2026-09-03) for hair_loss, dizziness and pancreatitis: their 2026-04-12 triples (1–3%, 2–5%, 0.5–1.2%) had no recorded derivation and their cited trial pages state no such figures; each is now one value at every tier from the same FDA Wegovy label — hair_loss 0.03 (Table 3: 3% on 2.4 mg, N=2,116, vs 1% placebo), dizziness 0.08 (Table 3: 8% vs 4%), and pancreatitis 0.002, which is NOT a proportion of patients like every other value in this table but the label's incidence RATE of 0.2 acute-pancreatitis cases per 100 patient-years of Wegovy exposure (4 adjudicated cases vs 1 on placebo, section 5) — read it with that unit. Figures served before 2026-09-04 for these three effects should not be cited.","confidenceNote":"`sourceDiversity` (formerly `confidence`, kept as a deprecated alias with the same value) measures SOURCE DIVERSITY, not precision: it is derived only from distinctSources (≤1 very_low, ≤3 low, ≤9 moderate, ≤24 high, ≥25 very_high) and is computed without reference to the confidence interval. It can read `moderate` on an estimate whose interval spans nearly the whole range — always read ciLowPct/ciHighPct alongside it, and treat a wide interval as the binding statement about how well we know the rate.","modifiers":{"femaleFactor":1.3,"ageFactor65plus":1.4,"giHistoryFactor":1.3,"diabetesFactor":1,"firstMonthFactor":1.5},"modifiersNote":"Odds ratios hand-coded at the 2026-04-12 seed with no per-modifier citation recorded — treat each as an expert-coded prior, not a sourced estimate. The FDR-corrected empirical estimator runs daily but no effect yet meets its evidence bar (model config v2 — its one post-seed change, 2026-09-04, re-sourced four static base rates by hand; zero empirical modifiers applied). See ?q=help for the full methodology note.","reportingFrequency":{"mentions":7,"distinctReports":26,"sharePct":26.9,"platforms":["reddit.com","drugs.com"],"note":"Share of distinct community reports (one row per source URL) that mention this effect. Counts only reports hosted on the community platform itself, and — corrected 2026-08-29 — only Reddit posts from the GLP-1, weight-management and diabetes subreddits we collect from: the scraper's subreddit restriction was not holding, and 159 of the previous 185 reports were posts matched on a symptom word in unrelated communities (r/gallbladders, r/AskDocs, r/pregnant). News-aggregator results are excluded, see platforms. The remaining base is small and cannot currently grow (Reddit has blocked our collector since 2026-05-28), so read every share with its distinctReports denominator. Not an incidence rate; not comparable to clinicalRates."},"userReportedSeverity":"Community reports describe it starting within the first 1-2 weeks and easing with diet changes. Fibre supplements, extra water, and gentle movement are the most frequently mentioned fixes; a few describe it persisting through the full titration period.","onsetDays":"Not stated by any clinical source on file.","durationWeeks":"Not stated by any clinical source on file.","managementTip":"Increase water intake, add fibre-rich foods gradually, consider a mild fibre supplement. Regular movement helps.","sources":[{"name":"Real-world evidence systematic review (PMC 2025)","type":"clinical","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12000858/","weight":0.3},{"name":"Viva Forum NL weight loss discussions (2025-2026)","type":"user_report","weight":0.4},{"name":"PCOM Safety review (2025)","type":"news","url":"https://www.pcom.edu/south-georgia/news/safety-benefits-and-side-effects-of-glp-1-weight-loss-medications.html","weight":0.3}]},"dataPointCount":151,"rateBase":{"note":"Only externally citable, non-duplicated rates support an estimate. Shares of spontaneous adverse-event reports (FAERS) are reported separately — they are not incidence. A source marked rateKind: \"serious_ae\" states a rate from a trial registry's SERIOUS adverse-events table for a term posted in no other table of the same arm — a real stated figure, but a floor on all-cause incidence, since the registry lists non-serious events only above the trial's reporting threshold.","clinical":{"statedRates":26,"distinctSources":13,"sourceEntries":13,"pooledEstimate":{"ratePct":11.8,"ciLowPct":1,"ciHighPct":56,"statedRates":26,"distinctSources":13,"sourceEntries":13,"seriousAeSources":0,"rateKindNote":"","rateKindNoteNl":"","confidence":"high","sourceDiversity":"high"},"confidenceNote":"`sourceDiversity` (formerly `confidence`, kept as a deprecated alias with the same value) measures SOURCE DIVERSITY, not precision: it is derived only from distinctSources (≤1 very_low, ≤3 low, ≤9 moderate, ≤24 high, ≥25 very_high) and is computed without reference to the confidence interval. It can read `moderate` on an estimate whose interval spans nearly the whole range — always read ciLowPct/ciHighPct alongside it, and treat a wide interval as the binding statement about how well we know the rate.","seriousAeSources":0,"sources":[{"name":"ClinicalTrials.gov results — A Study of Once-Daily Oral Orforglipron (LY3502970) in Japan — Constipation","url":"https://clinicaltrials.gov/study/NCT05931380#adverse-events","rate":0.32,"sampleSize":61,"rateKind":"incidence"},{"name":"ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Constipation","url":"https://clinicaltrials.gov/study/NCT06440980#adverse-events","rate":0.24,"sampleSize":215,"rateKind":"incidence"},{"name":"ClinicalTrials.gov results — A Study of LY3502970 in Japanese Participants With Type 2 Di — Constipation","url":"https://clinicaltrials.gov/study/NCT05086445#adverse-events","rate":0.333,"sampleSize":9,"rateKind":"incidence"},{"name":"ClinicalTrials.gov results — A Long-term Safety Study of Orforglipron (LY3502970) in Part — Constipation","url":"https://clinicaltrials.gov/study/NCT06010004#adverse-events","rate":0.298,"sampleSize":135,"rateKind":"incidence"},{"name":"ClinicalTrials.gov results — Research Study to Investigate How Well Semaglutide Tablets T — Constipation","url":"https://clinicaltrials.gov/study/NCT05132088#adverse-events","rate":0.209,"sampleSize":134,"rateKind":"incidence"},{"name":"ClinicalTrials.gov results — Semaglutide Treatment, Appetite, and Eating Behavior: Long-t — Constipation","url":"https://clinicaltrials.gov/study/NCT05548647#adverse-events","rate":0.528,"sampleSize":72,"rateKind":"incidence"},{"name":"PubMed — A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic ","url":"https://pubmed.ncbi.nlm.nih.gov/33185364/","rate":0.22,"sampleSize":82,"rateKind":"incidence"},{"name":"ClinicalTrials.gov results — A Study of Tirzepatide (LY3298176) in Participants With Obes — Constipation","url":"https://clinicaltrials.gov/study/NCT04184622#adverse-events","rate":0.163,"sampleSize":636,"rateKind":"incidence"},{"name":"ClinicalTrials.gov results — Semaglutide Effects on Heart Disease and Stroke in Patients  — Constipation","url":"https://clinicaltrials.gov/study/NCT03574597#adverse-events","rate":0.081,"sampleSize":8803,"rateKind":"incidence"},{"name":"ClinicalTrials.gov results — Research Study Investigating How Well Semaglutide Works in P — Constipation","url":"https://clinicaltrials.gov/study/NCT03552757#adverse-events","rate":0.151,"sampleSize":403,"rateKind":"incidence"},{"name":"ClinicalTrials.gov results — A Study of Tirzepatide (LY3298176) Compared With Dulaglutide — Constipation","url":"https://clinicaltrials.gov/study/NCT04255433#adverse-events","rate":0.121,"sampleSize":6647,"rateKind":"incidence"},{"name":"ClinicalTrials.gov results — A Study of LY3437943 in Participants Who Have Obesity or Are — Constipation","url":"https://clinicaltrials.gov/study/NCT04881760#adverse-events","rate":0.112,"sampleSize":69,"rateKind":"incidence"},{"name":"ClinicalTrials.gov results — STEP 1: Research Study Investigating How Well Semaglutide Wo — Constipation","url":"https://clinicaltrials.gov/study/NCT03548935#adverse-events","rate":0.234,"sampleSize":1306,"rateKind":"incidence"}],"excluded":{"seed_unverified":3,"spontaneous_report_share":4,"no_rate":23},"usesPublishedFallback":false},"community":{"statedRates":0,"distinctSources":0,"sourceEntries":0,"excluded":{"seed_unverified":7,"no_rate":86,"aggregator_result":2},"usesPublishedFallback":true},"spontaneousReportShares":[{"source":"FDA FAERS — semaglutide — CONSTIPATION","url":"https://api.fda.gov/drug/event.json?search=patient.drug.openfda.generic_name:\"semaglutide\"","shareOfReports":0.056,"reports":4612},{"source":"FDA FAERS — tirzepatide — CONSTIPATION","url":"https://api.fda.gov/drug/event.json?search=patient.drug.openfda.generic_name:\"tirzepatide\"","shareOfReports":0.03,"reports":4190},{"source":"FDA FAERS — liraglutide — CONSTIPATION","url":"https://api.fda.gov/drug/event.json?search=patient.drug.openfda.generic_name:\"liraglutide\"","shareOfReports":0.029,"reports":1515},{"source":"FDA FAERS — orforglipron — CONSTIPATION","url":"https://api.fda.gov/drug/event.json?search=patient.drug.openfda.generic_name:\"orforglipron\"","shareOfReports":0.07,"reports":81}]},"dataPointsBySource":{"clinical":52,"regulatory":4,"user_report":71,"news":24},"sampleDataPoints":[{"sourceName":"Real-world evidence systematic review (PMC 2025)","sourceType":"clinical","sourceUrl":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12000858/","extractedRate":0.05,"extractedSeverity":"mild","extractedSampleSize":200,"extractionConfidence":"high","scrapedAt":"2026-04-06T11:45:17.713Z"},{"sourceName":"Real-world evidence systematic review (PMC 2025)","sourceType":"clinical","sourceUrl":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12000858/","extractedRate":0.12,"extractedSeverity":"mild","extractedSampleSize":500,"extractionConfidence":"high","scrapedAt":"2026-04-06T11:45:17.713Z"},{"sourceName":"Real-world evidence systematic review (PMC 2025)","sourceType":"clinical","sourceUrl":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12000858/","extractedRate":0.18,"extractedSeverity":"mild","extractedSampleSize":300,"extractionConfidence":"high","scrapedAt":"2026-04-06T11:45:17.713Z"},{"sourceName":"Viva Forum NL weight loss discussions (2025-2026)","sourceType":"user_report","sourceUrl":"https://magistra.health/nl/science#constipation","extractedRate":0.05,"extractedSeverity":"mild","extractedSampleSize":200,"extractionConfidence":"high","scrapedAt":"2026-04-06T11:45:17.713Z","excludedFromPublished":"off-topic source: not a GLP-1/weight-management/diabetes community report"},{"sourceName":"Viva Forum NL weight loss discussions (2025-2026)","sourceType":"user_report","sourceUrl":"https://magistra.health/nl/science#constipation","extractedRate":0.12,"extractedSeverity":"mild","extractedSampleSize":500,"extractionConfidence":"high","scrapedAt":"2026-04-06T11:45:17.713Z","excludedFromPublished":"off-topic source: not a GLP-1/weight-management/diabetes community report"}],"lastUpdated":"2026-09-10"}